SWOT Analysis for Adaptimmune Therapeutics Plc - ADR

Positive Breakout First Resistance ( LTP > R1)
Relative Outperformance versus Industry over 1 Month
Annual Profit Growth higher than Sector Profit Growth
PEG lower than Industry PEG
Relative Outperformance versus Industry over 1 Month
Efficient in managing Assets to generate Profits - ROA improving since last 2 year
Strong cash generating ability from core business - Improving Cash Flow from operation for last 2 years
Annual Net Profits improving for last 2 years
Positive Breakout (LTP > R1)
Top Gainers
Stock with Low PE (PE < = 10)

Companies with growing costs YoY for long term projects
Companies with High Debt
Bearish Stocks - Stocks with Medium to Low Trendlyne Momentum Score
Low DVM Stocks - Stocks to Exercise Caution On
Lowest Momentum Scores (Technical Scores)
Stocks with Expensive Valuations according to the Trendlyne Valuation Score
Low durability companies
Weak Stocks (DVM)
Inefficient use of shareholder funds - ROE declining in the last 2 years
Highest fall from 52 Week High
Low Piotroski Score : Companies with weak financials
Declining Net Cash Flow : Companies not able to generate net cash
Book Value Per Share deteriorating for last 2 years
Stocks Underperforming their Industry Price Change in the Quarter